Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
This funding supports preclinical and patient-based research to identify the biological mechanisms by which incretin mimetics—GLP-1, GIP-1, or dual GLP-1/GIP-1 agents—affect cancer risk. Applicants should focus on pathways and dynamic treatment-related changes, not short-term outcomes like weight loss or diabetes. The evidence so far suggests these drugs may increase risk for some obesity-rela…
Source
Award
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health
-
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
National Institutes of Health
-
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
National Institutes of Health
-
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
National Institutes of Health
-
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
National Institutes of Health
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers